Milrinon Hikma (Milrinone)

Milrinone, the active ingredient in Milrinon Hikma, is a phosphodiesterase‑3 inhibitor presented as an intravenous solution for intravenous use. It treats acute decompensated heart failure and cardiogenic shock in hospitalized patients who require rapid hemodynamic support.

GNH USA supplies Milrinon Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone is used in the management of acute cardiac conditions that require inotropic support.

Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion, helping stabilize patients. Cardiogenic shock: provides rapid hemodynamic stabilization by increasing contractility and lowering systemic vascular resistance. Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility to support circulation during the postoperative period.

Milrinone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: reduced blood pressure, especially with rapid infusion. - Arrhythmias: premature ventricular contractions or tachyarrhythmias. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of the skin. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: profound drop in blood pressure requiring intervention. - Ventricular arrhythmias: life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Thrombocytopenia: significant drop in platelet count. - Anaphylactic reactions: rare but potentially fatal allergic response. - Elevated liver enzymes: indication of hepatic stress.

Milrinon Hikma requires careful clinical monitoring and adherence to safety guidelines.

Renal impairment: adjust monitoring and dosage as needed. Hypotension: monitor blood pressure closely during infusion. Arrhythmias: avoid in patients with pre‑existing ventricular arrhythmias. Concomitant vasodilators: use with caution due to additive hypotensive effect. Pregnancy: safety not established; use only if benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinon Hikma can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Concurrent use with other phosphodiesterase‑3 inhibitors: risk of excessive vasodilation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase milrinone plasma levels. - Potent vasodilators (e.g., nitroprusside): can cause severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑adrenergic agonists: additive inotropic effect may precipitate tachyarrhythmias. - Diuretics: electrolyte shifts may augment arrhythmic risk. - Anticoagulants: potential for increased bleeding if platelet counts fall.